Baillie Gifford & CO Bristol Myers Squibb CO Transaction History

Baillie Gifford & CO

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 03, 2023	BUY	$65.71 - $74.53 $4,796 - $5,440	73 Added 15.94%	531 $36,000
Q3 2022 Oct 27, 2022	SELL	$0.13 - $76.84 $3 - $2,305	-30 Reduced 6.15%	458 $33,000
Q2 2022 Aug 08, 2022	BUY	$72.62 - $79.98 $1,815 - $1,999	25 Added 5.4%	488 $38,000
Q1 2022 May 05, 2022	BUY	$61.48 - $73.72 $2,213 - $2,653	36 Added 8.43%	463 $34,000
Q4 2021 Jan 20, 2022	SELL	$53.63 - $62.52 $2,520 - $2,938	-47 Reduced 9.92%	427 $27,000
Q3 2021 Oct 19, 2021	SELL	$59.17 - $69.31 $5,206 - $6,099	-88 Reduced 15.66%	474 $28,000
Q2 2021 Aug 02, 2021	SELL	$61.91 - $67.42 $2,785 - $3,033	-45 Reduced 7.41%	562 $38,000
Q1 2021 May 06, 2021	BUY	$59.34 - $66.74 $1,424 - $1,601	24 Added 4.12%	607 $38,000
Q4 2020 Feb 10, 2021	BUY	$57.74 - $65.43 $33,662 - $38,145	583 New	583 $36,000
Q3 2017 Oct 20, 2017	SELL	$55.23 - $63.74 $9.82 Million - $11.3 Million	-177,742 Closed	0 $0
Q2 2017 Aug 10, 2017	BUY	N/A	177,742	177,742 $9.9 Million

2,428

1.5B

29.7M

32.2M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Baillie Gifford & CO, based on Form 13F filings with the SEC.

Stay updated on Baillie Gifford & CO with notifications on news.